Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Dana Taylor
Authored Items
Multiple Myeloma Therapy in 2015: “An Extraordinary Moment in Oncology”
Dana Taylor
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
in
Multiple Myeloma
,
Oncology
All-Oral Regimen May Become a New Standard of Care in Advanced Multiple Myeloma
Dana Taylor
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
in
Multiple Myeloma
,
Oncology
Consistent Benefit Over Time in Elotuzumab Studies
Dana Taylor
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
in
Multiple Myeloma
,
Oncology
Daratumumab Improves Overall Survival in Multiple Myeloma
Dana Taylor
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
in
Multiple Myeloma
,
Oncology
Last modified: February 22, 2016
